Alzamend Neuro, Inc. Corporate Presentation April 2022 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the "Company" or "

Alzamend Neuro, Inc. Corporate Presentation April 2022

SAFE HARBOR STATEMENT 2 This presentation and other written

or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the "Company" or " Alzamend

") contain "forward looking statements" within the meaning of Section 27 A of the Securities Act of 1933 , as amended,

and Section 21 E of the Securities Exchange Act of 1934 , as amended . Forward - looking statements reflect the current view about future

events . Statements that are not historical in nature, such as forecasts for the industry in which we operate, and which may be identified

by the use of words like " expects," "assumes," "projects," "anticipates," "estimates,"

"we believe," "could be," "future,"" or the negative of these terms and other words of similar meaning,

are forward - looking statements . Such statements include, but are not limited to, statements contained in this presentation relating

to our business, business strategy, expansion, growth and product candidates and the timing of their development, sales and marketing

strategy and capital outlook . Forward - looking statements are based on management's current expectations and assumptions regarding

our business, the economy and other future conditions and are subject to inherent risks, uncertainties and changes of circumstances that

are difficult to predict and may cause actual results to differ materially from those contemplated or expressed . We caution you therefore

against relying on any of these forward - looking statements . These risks and uncertainties include those risk factors discussed in

Part I, "Item 1 A . Risk Factors" of our Annual Report on Form 10 - K for the fiscal year ended April 30 , 2020 (the "

2020 Annual Report") and other information contained in subsequently filed current and periodic reports, each of which is available

on our website and on the Securities and Exchange Commission's website ( www . sec . gov ) . Any forward - looking statements are

qualified in their entirety by reference to the risk factors discussed in the 2020 Annual Report . Should one or more of these risks

or uncertainties materialize (or in certain cases fail to materialize), or should the underlying assumptions prove incorrect, actual

results may differ significantly from those anticipated, believed, estimated, expected, intended or planned . Important factors that

could cause actual results to differ materially from those in the forward - looking statements include : risks related to performing

clinical studies ; the ability to initiate and complete clinical studies and report data therefrom ; whether the results from clinical

studies will validate and support the safety and efficacy of our product candidates ; competition from other products ; risks in product

development ; the ability to protect our intellectual property rights ; impact of any litigation or infringement actions brought against

us ; market acceptance if we can commercialize our product candidates ; inability to raise capital to fund clinical trials ; and changes

in government regulation . Factors or events that could cause our actual results to differ may emerge from time to time, and it is not

possible for us to predict all of them . We cannot guarantee future results, levels of activity, performance or achievements . Except

as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward - looking

statements to conform these statements to actual results . All forecasts are provided by management in this presentation and are based

on information available to us at this time and management expects that internal projections and expectations may change over time .

In addition, the forecasts are based entirely on management's best estimate of our future financial performance given our product

candidate development and market opportunities .

Alzamend Neuro, Inc. information cannot be disclosed or reprinted

without prior written permission. TABLE OF CONTENTS 3 Introduction Company Overview 4 - 5 Overview of Alzheimer's Disease Alzheimer's

Disease 6 Economic Burden 7 Therapeutic Landscape 8 Our Science General Scientific Overview 9 - 10 AL001 (LISPRO) - Phase I Clinical

Study and Results 11 - 12 AL001 (LISPRO) - Non - Clinical 13 - 15 AL002 (E22W) - Non - Clinical 16 - 17 Specific Details

Intellectual Property 18 Competitive Landscape and Market Opportunity 19 - 20 Final Details Our Team 21 - 23

Alzamend Neuro, Inc. information cannot be disclosed or reprinted

without prior written permission. Company Overview INTRODUCTION NASDAQ: ALZN 4 Industry Biotechnology Sector Small Molecule / Cell Therapy

Founded 2016 IPO June 15, 2021 Last Reported Cash $11.8 Million (as of January 31, 2022 per 10 - Q filed on March 15, 2022) Recent Financing

$4.0 Million (Milestone Payment for Phase I Completion) Location Atlanta, Georgia (Corporate Headquarters)

Alzamend Neuro, Inc. information cannot be disclosed or reprinted

without prior written permission. Company Overview INTRODUCTION Company History Current Projects 5 AL001 (aka LISPRO): an ionic

cocrystal of lithium for the treatment of Alzheimer's Disease and other neurodegenerative diseases and psychiatric disorders. AL002

(aka E22W): a cell - based therapeutic vaccine that seeks to restore the ability of the patients' immunological system

to combat Alzheimer's Disease. Early clinical - stage biopharmaceutical company dedicated to: Researching, developing and

commercializing preventions , treatments and cures for neurodegenerative diseases and psychiatric disorders. Working on two therapeutics

licensed from the University of South Florida Research Foundation, Inc. , one of the top 20 institutions in the nation for patented research

and their portfolio of proprietary solutions.

Alzamend Neuro, Inc. information cannot be disclosed or reprinted

without prior written permission. Alzheimer's Disease OVERVIEW OF ALZHEIMER'S DISEASE 6 Alzheimer's Disease: Alzheimer's

Disease is an irreversible, progressive brain disorder that slowly destroys memory and cognitive skills , and eventually the ability

to carry out the simplest tasks . In most people with Alzheimer's Disease, symptoms first appear in their early to mid - 60's.

Estimates vary, but experts suggest that more than 6.5 million Americans may have Alzheimer's Disease, considered by many as "

the most feared" disease . Alzheimer's Disease has no current cure , but five treatments for symptoms are available today

while research continues. Key Statistics: 7th leading cause of death in the United States Between 2000 and 2019, deaths from heart disease

have decreased 7.3% while deaths from Alzheimer's Disease have increased 145% 13 million Americans are projected to be living with

Alzheimer's Disease by 2050 1 - in - 9 Americans over the age of 65 are estimated to be afflicted with Alzheimer's Disease

https://www.alz.org/media/Documents/alzheimers - facts - and - figures.pdf

Alzamend Neuro, Inc. information cannot be disclosed or reprinted

without prior written permission. Important Implications Economic Burden 1. In 2022, the estimated healthcare costs for treating individuals

with Alzheimer's Disease in the United States will be $321 billion , including $206 billion in Medicare and Medicaid payments 2.

More than 11 million Americans (family members) provide unpaid care for people with Alzheimer's Disease or other dementias - an

estimated 16 billion hours of care valued at nearly $272 billion 3. By 2050, treatment for Alzheimer's Disease/dementia could rise

to nearly $1 trillion per year , most of which will be funded by Medicare & Medicaid 7 https://www.alz.org/media/Documents/alzheimers

- facts - and - figures.pdf OVERVIEW OF ALZHEIMER'S DISEASE

Alzamend Neuro, Inc. information cannot be disclosed or reprinted

without prior written permission. Therapeutic Landscape 8 OVERVIEW OF ALZHEIMER'S DISEASE https://alz - journals.onlinelibrary.wiley.com/pb

- assets/DADM/TRCI%20Drug%20Pipeline%20Infographic - DoctorAudience - 2021%20 - %20No%20 AA%20logo - 1624914037.jpg

Alzamend Neuro, Inc. information cannot be disclosed or reprinted

without prior written permission. Pipeline GENERAL SCIENTIFIC OVERVIEW 9 Product Candidate Indication Pre - Clinical Phase I Phase II

Phase III FDA Approval AL001 Alzheimer's Disease Bipolar Disorder Major Depressive Disorder (Depression)

Post - Traumatic Stress Disorder (PTSD) AL002 Alzheimer's Disease Awaiting results from a Phase IIa Multiple Ascending

Dose/ Tolerability Alzheimer's Patient Study to Submit IND to Initiate a Phase II Trial Phase IIa commencing in May 2022 Awaiting

results from a Phase IIa Multiple Ascending Dose/ Tolerability Alzheimer's Patient Study to Submit IND to Initiate a Phase II Trial

Awaiting results from a Phase IIa Multiple Ascending Dose/ Tolerability Alzheimer's Patient Study to Submit IND to Initiate a Phase

II Trial Submitting IND in June 2022

Alzamend Neuro, Inc. information cannot be disclosed or reprinted

without prior written permission. Overview of Our Science GENERAL SCIENTIFIC OVERVIEW 10 Therapeutic Drug Synopsis Strength Status AL001

Use of patented Ionic Cocrystal (ICC) technology delivering a therapeutic combination of Lithium, Proline, and Salicylate

Lithium as a treatment of agitation and other possible symptoms in patients with indication of Alzheimer's Disease Other

potential indications: Dementia, Parkinson's Disease, ALS, Depression, Bi - Polar Disorder, Mania, PTSD, Suicidality, etc.

Exclusive license for ICC delivery system to treat Alzheimer's Disease Potential for "breakthrough therapy"

designation from FDA Seeking a 505(b)(2) clinical trial pathway from FDA Formulation may importantly expand the range

of therapeutic categories amenable to lithium treatments, with enhanced safety Has the potential of becoming the replacement

for all lithium therapies on the market Commencing Phase IIa for Alzheimer's in May 2022 AL002 A patented method

using a mutant peptide sensitized cell as a cell - based therapeutic vaccine that reduces beta - amyloid plaque and seeks to restore

the ability of the patient's immunological system to combat Alzheimer's Disease. Also seeks to mitigate adverse reactions

from a patient's immunological system experienced during pre - clinical trials including the highly publicized Elan study (AN -

1972) Adjuvant - free therapeutic vaccine designed for the treatment and prophylactics of Alzheimer's Disease Difficult

to manufacture and hence not easily replicated by competitors Potential for "breakthrough therapy" status via FDA

Antibody responses induced after one inoculation (Pre - Clinical) and lasted for 4 months Inflammation cytokines like

IL1 and TNF.alpha, which are considered being related to inflammation didn't increase with antibody level increase Submitting

IND for combined Phase I/II in June 2022

Alzamend Neuro, Inc. information cannot be disclosed or reprinted

without prior written permission. AL001 Phase I Trial 11 Study No. Study Title Description Status AL001 - ALZ01 (US) A randomized, balanced,

Phase I, single - dose, open - label, two - treatment, two - period, two sequence, crossover, relative bioavailability study to investigate

lithium pharmacokinetics and safety of AL001 formulation compared to a marketed immediate release lithium carbonate formulation in healthy

subjects. To assess the relative bioavailability of the AL001 lithium formulation relative to a marketed lithium carbonate formulation

in healthy subjects for the purpose of determining potential clinically safe and effective AL001 dosing in future studies. To